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Included among the accepted medical
dogmas are: (1) exposure to tobacco
smoke, either directly or indirectly, is inju-
rious to health; and (2) new blood vessel
formation (neoangiogenesis) is essential
for tumor growth. In this issue of Cancer
Cell, Zhu and coworkers demonstrate a
link between these two phenomena
(Zhou et al., 2003). Before we discuss
how they demonstrated the connection
and the significance of their findings,
some background information needs to
be reviewed.
Usage of tobacco products results in
many health hazards, including cardio-
vascular disease, nonmalignant respira-
tory disease, and cancer. Smokers have
increased rates of many cancers, espe-
cially those arising in the lung, head and
neck, bladder, and cervix. More than
4000 compounds have been identified in
cigarette smoke, more than 60 of which
are known carcinogens and are present
both in the particulate and vapor phas-
es of cigarette smoke (Hecht, 2002).
The major carcinogens include the
polycyclic aromatic hydrocarbons and
N-nitrosamines. Cigarette smoke may
be inhaled directly by smokers (main-
stream smoke), released from the burn-
ing end of cigarettes (sidestream
smoke), or exhaled by smokers. The lat-
ter two forms constitute environmental
tobacco smoke (ETS, or second hand
smoke) that affects all individuals in the
vicinity of smokers. ETS is harmful,
although dilution by environmental air
makes it less dangerous than main-
stream smoke. While the US is among
the leading nations in the stringency of
its laws banning smoking in public
places, cotinine, a metabolic product of
nicotine, can be detected in the serum of
most nonsmokers, indicating wide-
spread exposure to ETS (Brownson et
al., 2002). While the increased cancer
risks of ETS are modest, the total weight
of the evidence is that it is a human car-
cinogen responsible for an estimated
3000 lung cancer deaths in never-smok-
ers (Brownson et al., 2002).
The tobacco engine is powered by
nicotine, and cigarettes have been
referred to as nicotine delivery devices.
Nicotine, while a weak carcinogen, is
one of the most addictive substances
known. The concentration of nicotine in
sidestream smoke is greater than its
concentration in mainstream smoke.
Nicotine exerts its cognitive and addic-
tive properties by interacting with neu-
ronal nicotinic acetylcholine receptors
that are widely distributed in the brain
(Itier and Bertrand, 2001; Leonard and
Bertrand, 2001). However, nicotinic
receptors are also expressed in other
tissues, including vascular endothelium
(Conklin et al., 2002; Heeschen et al.,
2003) and bronchial epithelium (Minna,
2003; West et al., 2003). Thus, nicotine
may promote carcinogenesis by indi-
rect mechanisms, including stimulation
of angiogenesis (Heeschen et al.,
2003), and by activating the Akt signal-
ing pathway in bronchial epithelial cells
(Minna, 2003; West et al., 2003).
Nicotine increases oxidative stress,
activates NF-κB, induces apoptosis,
and sensitizes cells to genotoxic and
xenobiotic stresses (Crowley-Weber et
al., 2003). Additional potential roles of
nicotine in carcinogenesis have been
discussed by Minna (2003).
The pioneering work by Folkman and
others has demonstrated that tumors
require neoangiogenesis (new blood
vessel formation) for growth, and several
clinical trials targeting tumor vasculature
are being conducted currently (Dredge
et al., 2003). The structure and composi-
tion of blood vessels and lymphatics vary
with their size, type, and location, but all
vessels are lined by endothelial cells.
Endothelial cells may arise from existing
differentiated cells or from circulating
endothelial cell precursors derived from
the bone marrow. Many molecules,
secreted both by malignant and nonma-
lignant cells, stimulate angiogenesis.
Neoangiogenesis commences early dur-
ing the multistage pathogenesis of lung
cancer, and angiogenic lesions are fre-
quent in the bronchi of smokers (Keith et
al., 2000). Nicotine, at concentrations
found in the plasma of smokers, stimu-
lates the proliferation of endothelial cells
acting via nicotinic acetylcholine recep-
tors, and, possibly, by other mechanisms
(Jain, 2001). In addition, nicotine stimu-
lates atheroma formation and the growth
of lung cancers (Jain, 2001).
Because nicotine is a major compo-
nent of ETS, Zhou and coworkers postu-
lated that ETS would accelerate tumor
angiogenesis (Zhou et al., 2003). They
demonstrate that exposure to ETS at lev-
els present in smoking environments
stimulated growth of a murine tumor
model, enhanced tumor vessel density,
and increased growth factors and circu-
lating endothelial cell precursors. To fur-
ther prove that the oncogenic effects of
ETS were mediated, at least in part, by
the angiogenic effects of nicotine, they
demonstrated that the effects were
reduced by mecamylamine, a nicotine
receptor antagonist, and by statins, com-
pounds that interfere with the formation
of endothelial precursor cells. As
tobacco smoke contains several thou-
sands of compounds, the possibility that
substances in ETS other than nicotine
contribute toward neoangiogenesis
should be considered.
What is the significance of these
findings? While the effects of nicotine on
neoangiogenesis have been known for a
few years, these observations have now
been extended to ETS. Although smok-
ing is the major cause of lung and some
other cancers, about 15% of lung can-
cers arise in lifetime never-smokers. ETS
is believed to be an important factor in
the causation of these tumors. Clearly,
ETS is harmful, and is associated with
diseases other than cancer. One poten-
tially reassuring finding is the observa-
tion that statins, drugs that are widely
used as cholesterol-lowering agents,
may decrease the carcinogenic effects of
ETS. The findings by Zhou et al. provide
further evidence that reduction of expo-
sure to ETS is a desirable goal of major
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Environmental tobacco smoke, carcinogenesis, and angiogenesis:
A double whammy?
In this issue of Cancer Cell, Zhu and coworkers demonstrate that environmental tobacco smoke (ETS) results in tumor
angiogenesis, and provide evidence that the responsible factor in ETS is nicotine. While a weak carcinogen, nicotine pro-
motes carcinogenesis by a number of different mechanisms.The authors’ findings provide further evidence of the harmful
effects of ETS and indicate the desirability of reducing exposure to it.
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public health importance. While smokers
may have the right to smoke, nonsmok-
ers should have the right to be protected
from harm resulting from the action of
smokers. Reduction of exposure to ETS
should be the goal of all nations.
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The E type cyclins and their catalytic
partner, CDK2, participate in the regula-
tion of retinoblastoma protein inactiva-
tion, establishment of the prereplication
complex (pre-RC), and initiation of S
phase (Figure 1); their participation in
these critical regulatory steps has result-
ed in the assumption that both cyclin E
and CDK2 are indispensable for cell
cycle progression. Support for this notion
was initially provided by experiments uti-
lizing a dominant negative CDK2 mole-
cule to demonstrate that CDK2 activity is
required for cell cycle progression of cer-
tain tumor-derived cell lines (van den
Heuvel and Harlow, 1993). An essential
role for E/CDK2 has two critical implica-
tions. First, as an essential enzyme, loss
of either component should impede
cell cycle progression. Second, as
unchecked cell proliferation is a hallmark
of human cancer, the cyclin E/CDK2
kinase should be a logical target for the
development of anticancer therapeutics.
In point of fact, cyclin E is overexpressed
in human breast cancer, and its overex-
pression correlates with poor prognosis
(Keyomarsi et al., 2002). However, two
papers now challenge the notion that the
cyclin E/CDK2 kinase is an essential
component of the cell cycle machine.
In one approach, cyclin E was elimi-
nated from the mouse via targeting of
both genes encoding E type cyclins,
cyclins E1 and E2 (Geng et al., 2003),
and in the second, CDK2 itself was dis-
rupted (Ortega et al., 2003). While the
phenotypes are not entirely overlapping
as one might expect, they do culminate
with the startling revelation that neither E
type cyclins nor CDK2 are strictly
required for either embryonic develop-
ment or for continuous cell cycle pro-
gression.
As with elimination of another G1
cyclin, cyclin D1 (Sicinski et al., 1995),
the elimination of E type cyclins resulted
in focal abnormalities. Defects were
observed in the development of cell
types that required repeated rounds of
endoreplication (repeated rounds of S
phase without intervening cell division)
such as trophoblast giant cells. Such a
phenotype might have been anticipated
from earlier examination of cyclin E func-
tion in Drosophila development (Sauer
and Lehner, 1995). Surprisingly, CDK2
ablation did not result in apparent
defects in endoreplication cycles.
Defects were also observed in spermato-
genesis in E2−/− and E1/E2−/− mice that
resulted in eventual male sterility.
CDK2−/− mice, like cyclin E deficient
mice, also exhibited defects in male
spermatogenesis. Additionally, CDK2−/−
mice also exhibited defective female
gametogenesis, implicating the cyclin
E/CDK2 kinase in the regulation of mei-
otic cell cycles.While it is far from settled,
Cell cycle progression without cyclin E/CDK2: Breaking down the
walls of dogma
G1 is the phase of the cell cycle wherein the cell is responsive to growth factor-dependent signals. As such, G1 regulation
is frequently disrupted in cancer through deregulation of cyclin/CDK activity; deregulation of G1 phase provides tumori-
genic cells with a growth advantage. Cyclin E, the regulatory cyclin for CDK2, is considered a requisite regulator of G1 pro-
gression. Cyclin E is overexpressed in cancer, suggesting that cyclin E/CDK2 deregulation contributes to tumorigenesis.
Two papers now challenge both the concept that cyclin E/CDK2 is a requisite component of the cell cycle machine and
efforts to develop cyclin E/CDK2 inhibitors as antiproliferative therapeutics.
